BML-266 A SIRT2 inhibitor

BML-266 (CAS 96969-83-4)

BML-266 | CAS 96969-83-4 is rated 5.0 out of 5 by 1.
  • y_2019, m_5, d_22, h_2
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_221371, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 84ms
  • REVIEWS, PRODUCT
Synonym: JFD00244
Application: A SIRT2 inhibitor
CAS Number: 96969-83-4
Molecular Weight: 478.55
Molecular Formula: C30H26N2O4
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

BML-266 is a structurally novel SIRT2 inhibitor (IC50 = 56.7 μM). SIRT2 is a deacetylase and a homolog of the yeast Sir2 protein, which is known to regulate epigenetic gene silencing. It has been shown that SIRT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis.


References

1. Kiviranta, Päivi H., et al., 2006. N,N'-Bisbenzylidenebenzene-1,4-diamines and N,N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors. Journal of medicinal chemistry. 49(26): 7907-11. PMID: 17181175

Physical State :
Solid
Solubility :
Soluble in DMSO (≥10 mg/mL), and water (<2 mg/mL).
Storage :
Store at -20° C
Melting Point :
~301.99° C (Predicted)
Boiling Point :
~780.2° C at 760 mmHg (Predicted)
Density :
~1.4 g/cm3 (Predicted)
Refractive Index :
n20D 1.73
IC50 :
SIRT2: IC50 = 56.7 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
2817242
MDL Number :
MFCD00208443
SMILES :
C1=CC=C2C(=C1)C(=O)C3=C(C=CC(=C3C2=O)NCCC4=CC=C(C=C4)O)NCCC5=CC=C(C=C5)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 65ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Sunami et al Sunami et al. (PubMed ID 23460888) found that the sirtuin inhibitor, BML-266, induced granulocytic differentiation in acute promyelocytic cells by inactivating SIRT2. -SCBT Publication Review
Date published: 2015-01-21
  • y_2019, m_5, d_22, h_2
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_221371, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 220ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.